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Proliferation of vascular smooth muscle cells (SMCs) is a critical process for the development of atherosclerosis and complications
of procedures used to treat atherosclerotic diseases, including postangioplasty restenosis, vein graft failure, and transplant vascu-
lopathy. Peroxisome proliferator-activated receptor (PPAR) γ is a member of the nuclear hormone receptor superfamily and the
molecular target for the thiazolidinediones (TZD), used clinically to treat insulin resistance in patients with type 2 diabetes. In ad-
dition to their eﬃcacy to improve insulin sensitivity, TZD exert a broad spectrum of pleiotropic beneﬁcial eﬀects on vascular gene
expression programs. In SMCs, PPARγ is prominently upregulated during neointima formation and suppresses the proliferative
response to injury of the arterial wall. Among the molecular target genes regulated by PPARγ in SMCs are genes encoding proteins
involvedintheregulationofcell-cycleprogression,cellularsenescence,andapoptosis.ThisinhibitionofSMCproliferationislikely
to contribute to the prevention of atherosclerosis and postangioplasty restenosis observed in animal models and proof-of-concept
clinical studies. This review will summarize the transcriptional target genes regulated by PPARγ in SMCs and outline the thera-
peutic implications of PPARγ activation for the treatment and prevention of atherosclerosis and its complications.
Copyright © 2008 F. Gizard and D. Bruemmer. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Most cardiovascular diseases result from complications of
atherosclerosis, which is a multifactorial process character-
ized by chronic inﬂammation, lipid accumulation, and the
formation of a complex atherosclerotic lesion [1]. Recruit-
ment of monocytes, their diﬀerentiation into macrophages,
and uptake of LDL-derived cholesterol are the major cellu-
lar events contributing to early fatty streak formation [2, 3].
Continued intracellular cholesterol accumulation results in
the generation of endogenous inducers of inﬂammatory and
proliferative gene expression and a broad range of cellular
and humoral responses contributing to lesion initiation and
progression [4]. The resulting chronic inﬂammatory state
and the enrichment of lipid-laden macrophages ultimately
lead to the formation of a complex atherosclerotic lesion [5].
Duringthecourseofatheroscleroticlesionformation,se-
creted growth factors and cytokines promote the migration
and proliferation of vascular smooth muscle cells (SMCs) to
contributetoneointimaformation[6].Thischronicprolifer-
ati v er esponseofSMCspr omot esfurtherlesiondev elopment
through the production of proinﬂammatory mediators and
the synthesis of extracellular matrix molecules, which is re-
quired for the retention of lipoproteins and often consti-
tutes the majority of the protein content of the advanced le-
sion responsible for luminal obstruction [1]. However, SMC
proliferation within the developing lesion may also exert
beneﬁcial eﬀects by forming a ﬁbrous cap covering the ad-
vanced atherosclerotic lesion, an important mechanism for
the stability of the plaque [7]. The result of this chronic pro-
cess is the development of an advanced atherosclerotic le-
sion, which may ultimately cause luminal obstruction and
ischemic complications.
Once occlusive atherosclerotic disease has developed, the
standardofcaremayincludeangioplasty,coronaryarteryby-
pass grafting, or cardiac transplantation. However, all cur-
rent treatment approaches are limited by a varying degree
of treatment failure and reocclusion of the arterial lumen.2 PPAR Research
Among the cellular mechanisms responsible for this failure
of the current interventional procedures used to treat occlu-
sive atherosclerotic diseases, such as postangioplasty resteno-
sis,transplantvasculopathy,andcoronaryarterybypassgraft
failure, SMC proliferation constitutes a prime mechanism
[6].Inthepastdecade,elegantprogressininterventionalcar-
diology has provided the introduction of drug-eluting stents
delivering rapamycin or paclitaxel into the vessel wall that
target SMC proliferation [8]. However, despite initial enthu-
siasm, the complete inhibition of the healing response using
these approaches may leave a thrombogenic vessel surface at
risk of in-stent thrombosis and vessel occlusion [9]. Thus,
despite these advances, ideal therapy for occlusive vascular
disease is still far from established.
In an era marked by the increasing prevalence of obe-
sity,diabetes,andcardiovasculardisease,membersofthenu-
clear hormone receptor superfamily have emerged as tran-
scription factors that regulate diverse aspects of metabolism
[10, 11]. In addition to their function to act as molecular
sensors of lipid and carbohydrate homeostasis, several mem-
bers of the nuclear hormone receptor family, including the
peroxisomeproliferatoractivatedreceptor(PPAR)γ,alsoex-
ert beneﬁcial pleiotropic eﬀects to reduce atherosclerosis and
its complications [12, 13]. PPARγ is the molecular target
for the synthetic thiazolidinediones (TZD), such as rosigli-
tazone and pioglitazone, clinically used as insulin sensitizers
in patients with type 2 diabetes [14]. Over the last decade, a
wealth of evidence has supported a beneﬁcial role for TZD
PPARγ agonists in the regulation of vascular gene expres-
sion programs [12, 13]. While PPARγ expression itself is in-
creased in response to vascular injury [15–17], its activation
by TZD suppresses SMC proliferation through several mech-
anismsinvolvingtheregulationofgenesencodingproteinsin
SMC migration [15], proliferation [15], diﬀerentiation [18],
senescence [19], and apoptosis [16]. In the following review,
we will discuss the role of PPARγ in vascular biology with
respect to the control of proliferative gene expression pro-
grams that underlie SMC proliferation and the development
of cardiovascular diseases.
2. PPARγ: A LIGAND-ACTIVATED TRANSCRIPTON
FACTOR EXPRESSED IN VASCULAR CELLS
The detailed structure and molecular biology of PPARγ have
previously been outlined in excellent review articles [11, 20].
Brieﬂy, the PPAR subfamily of nuclear receptors consists of
3 isoforms, that is, PPARα (NR1C1), PPARβ (also known
as δ, NR1C2), and PPARγ (NR1C3). PPARs regulate gene
expression upon heterodimerization with the retinoid X re-
ceptor (RXR, or NR2B) and subsequent binding to speciﬁc
response elements located in the promoter regions of target
genes. Although presently there are no proven pathways for
endogenous ligands in vivo, all PPARs are activated in vitro
by fatty acids (FAs). PPARγ is activated by the prostaglandin
D2 derivative 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2)
[21] and forms of oxidized linoleic acid, 9- and 13(S)-HODE
[22]. Synthetic PPARγ ligands include TZD, such as trogli-
tazone, rosiglitazone, and pioglitazone, as well as non-TZD
derivates. PPARγ is predominantly expressed in adipose tis-
sue and has been characterized as an important regulator
of adipocyte diﬀerentiation and glucose homeostasis [14].
Based on their eﬃcacy to improve insulin sensitivity, the
TZD PPARγ ligands rosiglitazone and pioglitazone are cur-
rently being utilized in clinical practice to treat insulin resis-
tance in patients with type 2 diabetes [23, 24].
In addition to the metabolic eﬀect of PPARγ, the re-
ceptor is expressed in atherosclerotic lesions [15, 25]a n d
in all vascular cell types including endothelial cells (EC)
[26],macrophages[27],Tlymphocytes[28],andSMCs[29].
In EC, PPARγ is activated in response to atheroprotective
laminar ﬂow [30]. Ligand-induced activation of PPARγ in
these cells suppresses the expression of genes responsible
for the adhesion of monocytes to the endothelium (i.e.,
VCAM-1 [31, 32], ICAM-1 [33]) and their transendothe-
lial migration [34], which are both crucial early pro-
cesses for the subsequent development of atherosclerosis. In
macrophage biology, PPARγ has been demonstrated to sup-
press inﬂammatory gene expression and to decrease intracel-
lular lipid accumulation and foam-cell formation [35, 36].
Finally, increased PPARγ expression has been demonstrated
in neointimal layers during atherosclerotic lesion develop-
ment [15, 25]. Concomitant with the phenotypic shift from
quiescent SMCs resident in the uninjured vessel wall to pro-
liferating SMCs in the neointima, PPARγ expression is in-
duced in the neointima following vascular injury [15, 16].
Considering the importance of SMC proliferation during
atherosclerosis and its complications [6], this increased ex-
pression of PPARγ in neointimal SMCs has provided an im-
portant rationale to further exploit the role of PPARγ for
the proliferative response that underlies the development of
neointima formation and atherosclerotic cardiovascular dis-
eases.
3. TRANSCRIPTIONAL REGULATION OF SMOOTH
MUSCLE CELL PROLIFERATION BY PPARγ LIGANDS
The physiological state of the SMCs in the arterial wall is de-
termined by endogenous and exogenous signals, and often
theendpointthatinterpretatesthesesignalsisgenetranscrip-
tion [37]. Emerging evidence has implicated PPARγ as a key
transcriptional modulator of SMC function. In the follow-
ing section, we outline the role of PPARγ in the regulation of
diverse SMC processes including cell proliferation, cell-cycle
progression, senescence, and apoptosis (see Figure 1).
3.1. RegulationofSMCproliferationandcell-cycle
progressionbyPPARγ agonists
Mitogenic growth factors secreted during vascular injury
converge into a ﬁnal common signaling pathway regu-
lating the proliferative response of SMCs: the cell-cycle
[6] (see Figure 2). While SMCs are in a quiescent state
(G0) in the uninjured artery, they transit in response to
mitogenic stimulation through the G1 phase of the cell-
cycle and ultimately enter S phase to undergo replication
[38]. Cell-cycle progression is under the control of cy-
clins and cyclin-dependent kinases (CDKs), which phos-
phorylate the retinoblastoma gene product (pRB) [39]. pRBF. Gizard and D. Bruemmer 3
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Figure 1: Cellular mechanisms involved in the inhibition of SMC proliferation by PPARγ during cardiovascular diseases. PPARγ regulates
genes encoding proteins involved in diverse SMC processes including cell proliferation, cell-cycle progression, senescence, and apoptosis.
phosphorylation represents the critical checkpoint of the
G1→S phase transition and increased pRB phosphorylation
correlates with the induction of SMC proliferation in in-
jured vessels [40, 41]. Consistent with this, maintenance of
high levels of phosphorylated pRB is required for the de-
velopment of intimal hyperplasia. Upon pRB phosphoryla-
tion, sequestered E2F transcription factors are released to in-
duce the transcription of genes involved in the regulation
of S phase DNA synthesis [42]. Through CDK-inhibitors
(CDKI), including p27Kip1, the activity of cyclin/CDK com-
plexes in quiescent SMCs is inhibited providing a second
layer of regulation [43, 44]. In response to mitogens, p27Kip1
undergoes ubiquitination and degradation through the pro-
teasome pathway allowing CDK/cyclin complexes to phos-
phorylate pRB [45]. Therefore, mitogen-induced degrada-
tion of p27Kip1 is an initial requirement for pRB phospho-
rylation and subsequent G1→S cell-cycle progression [46].
PPARγ ligands have been demonstrated in various
studies to prevent mitogen-induced SMC proliferation and
the mechanisms by which this inhibition of proliferation
occurs appear to involve an arrest in the G1 phase of the
cell cycle [47–49]. The growth-inhibitory eﬀects of PPARγ
agonists were ﬁrst associated with their ability to prevent
mitogen-induceddegradationoftheCDKIcyclin-dependent
kinase inhibitor (CDKI) p27Kip1, which inhibits the activ-
ity of cyclin/CDK and consequently reduces the cellular lev-
els of phosphorylated pRB [47]. Since in vivo gene trans-
fer of p27Kip1 signiﬁcantly inhibits neointimal cell prolifer-
ation [43], p27Kip1 likely constitutes an important target for
the anti-proliferative eﬀects of PPARγ activation. Consistent
with its function to suppress the activity of cyclin/CDK-
complexes, stabilization of p27Kip1 by PPARγ ligands has
been demonstrated to inhibit cyclin/CDK activity, an ef-
fect that ultimately translates into a prevention of mitogen-
induced pRB phosphorylation [47].
DNA microarray analysis further identiﬁed that
minichromosome maintenance proteins (MCM) 6 and 7 are
inhibited by PPARγ ligands in SMCs [50]. MCM proteins
r e p r e s e n tb o n aﬁ d eE 2 Ft a r g e tg e n e s[ 51] and play a central
role in the regulation of the initiation of DNA replication
ensuring that DNA replicates only once during cell cycle
(for review see [52]). In eukaryotes, MCM2–MCM7 are
recruited onto replication origins during the G1 phase of
the cell cycle and assembled into a heteromeric hexamer.
Formation of this prereplication complex, a process often
referred to as “replication licensing”, establishes the compe-
tence of this origin for the initiation of DNA replication in
the subsequent S phase. Therefore, the inhibition of MCM
gene expression by PPARγ ligands provides evidence that the
inhibitory eﬀects of PPARγ ligands on G1→S transition are
the result of targeting the pRB/E2F/MCM pathway.
3.2. PPARγ activationandinductionof
apoptosisinSMCs
In addition to the role of TZD in the regulation of G1→S
cell-cycleprogression,severalstudieshavedemonstratedthat
TZD induce apoptosis in SMCs [16, 53, 54]. Among the
regulated target genes mediating PPARγ-induced apopto-
sis is the growth-arrest and DNA damage-inducible gene
45 (GADD45) [53]. Molecular analyses demonstrated that
PPARγ-induced GADD45 gene transcription is mediated
through an Oct-1-dependent mechanism [53]. Although the
exact function of GADD45 remains unclear, GADD45 has
been implicated in growth suppression [55] and apoptosis
[56, 57]. Through its association with Cdc2, GADD45 dis-
rupts the interactions of Cdc2 with cyclin B1 and, thus, may
induce G2/M arrest [58]. The GADD45 gene, therefore, may
represent a unique target for drugs that induce cell-cycle ar-
rest, apoptosis, and diﬀerentiation such as PPARγ ligands.
The second pathway that has been demonstrated to in-
duce apoptosis by PPARγ ligands involves the induction of
transforming growth factor (TGF)-β by PPARγ [54]. TGF-β
is an essential cytokine involved in the control of the balance4 PPAR Research
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Figure 2: PPARγ targets cell-cycle progression. Phosphorylation of the retinoblastoma gene product (pRB) by speciﬁc G1 CDKs represents
the critical checkpoint of the G1/S transition of the cell cycle. pRB phosphorylation releases E2F allowing the expression of genes required
for DNA synthesis. By preventing the degradation of the CDK inhibitor (CDKI) p27Kip1,P P A R γ ligands inhibit mitogen-induced pRB
phosphorylationanddownstreamexpressionofkeyE2F-regulatedgenes(i.e.,MCMgenes)responsiblefortheinitiationofDNAreplication.
between proliferation and apoptosis in SMCs [59]. Previ-
ously, TZD-induced apoptosis of SMCs has been suggested
to depend on the induction of TGF-β and subsequent down-
stream nuclear recruitment of phospho-Smad2 [54]. In-
terestingly, TGF-β-induced apoptosis is partly mediated by
Smad-dependent expression of GADD45 [60]. Therefore, it
is possible if not likely that GADD45 constitutes a key down-
stream mediator of apoptosis induced by PPARγ activation.
A third mechanism that has been implicated in PPARγ-
induced SMC apoptosis involves the transcriptional induc-
tion of the interferon regulatory factor-1 (IRF-1), a tran-
scriptional factor with anti-proliferative and proapoptotic
properties. Lin et al. recently demonstrated that both TZD
and PPARγ overexpression upregulate IRF-1 expression in
SMCs [61]. Reducing IRF-1 expression by antisense ap-
proaches attenuated PPARγ-induced SMC apoptosis sug-
gesting that the PPARγ-regulated IRF-1 pathway contributes
to the proapoptotic eﬀects observed with TZD.
3.3. RegulationofSMCtelomeraseand
senescencebyPPARγ ligands
Telomerase has been linked to multiple developmental pro-
cessesincludingcellproliferation,senescence,andaging[62–
64]. Telomeres, the DNA-protein complexes at the ends of
chromosomes,arestabilizedbytheribonucleoproteintelom-
erase reverse transcriptase (TERT) to serve as protective
capping and to prevent cellular senescence [65, 66]. In most
adult cells TERT expression and telomerase activity are re-
pressed and telomeres shorten during tissue renewal [67],
andithasbeenproposedthatthistelomereexhaustionisrate
limiting for lifespan [68]. Loss of telomere length beyond a
critical threshold results in cellular senescence [59], a state in
whichcellsareunresponsivetomitogenicstimuli[69].These
molecular features of telomerase to prevent senescence are
highly conserved among eukaryotes and act on somatic cells
as biological clock to ultimately result in permanent growth
arrest and entry into replicative senescence [70].
In SMCs, telomerase activity is required for cell pro-
liferation, and disruption of telomerase activity reduces
atherosclerosis and neointima formation [71–73]. TERT is
the limiting factor for telomerase activation in response to
mitogenic stimuli and TERT antisense oligonucleotides in-
hibit SMC proliferation [71, 72]. This suggests that TERT
may play an important role in the regulation of SMC pro-
liferation and neointima formation. A recent study demon-
strated that mitogen-induced telomerase activity in SMCs is
inhibited by ligand-induced and constitutive PPARγ activa-
tion [19]. The transcriptional mechanisms responsible for
the suppression of telomerase activity by PPARγ ligands in-
volve an inhibition of Ets-1-dependent transactivation of the
TERTpromoter[19].Ets-1isanearlyresponsegenethatme-
diatesavarietyofgrowthsignalsinneointimalSMCprolifer-
ation [74]; and atherosclerosis [75]a n dP P A R γ ligands have
been reported to inhibit Ets-1 expression [76]. The relevance
of telomerase as target for PPARγ was further demonstrated
in SMCs overexpressing telomerase, in which the eﬃcacy of
PPARγ ligand pioglitazone to inhibit cell proliferation is lost
[19]. These studies indicate that telomerase constitutes an
important molecular target for the antiproliferative eﬀects of
PPARγ activation in SMCs.
3.4. Ligand-receptorrelationshipandspeciﬁcity:
isTZD-regulatedgeneexpressioninSMCs
PPARγ-dependent?
Although the above-described evidence outlines the ability
of TZD to suppress SMC proliferation and induce apoptosis,F. Gizard and D. Bruemmer 5
it remains controversial whether the cell-cycle-inhibitory ef-
fects of TZD occur through a ligand-dependent activation
of PPARγ. Several experimental approaches have been used
by diﬀerent investigators to speciﬁcally address this question,
including PPARγ-deﬁcient cells [48, 77], overexpression
of either dominant-negative or constitutively-active PPARγ
mutants [19, 50, 53, 78], or pharmacologic inhibition of
PPARγ [16, 53, 54, 61]. In PPARγ-deﬁcient embryonic stem
cells, TZD have been demonstrated to inhibit cell prolifera-
tion, which indicated that this eﬀect might occur indepen-
dent of their binding and activation of PPARγ [77]. In con-
trast to these earlier studies in stem cells, overexpression of a
dominant-negativePPARγ mutanthasbeendemonstratedto
increaseSMCproliferationinvitroandneointimaformation
in vivo (discussed in Section 4.1) pointing to a role of PPARγ
to function as an endogenous repressor of SMC prolifera-
tion[78].Complementarytotheseobservations,overexpres-
sion of a constitutively-active PPARγ induces SMC apopto-
sis in the absence of ligand [53] while pharmacologic inhi-
bition of PPARγ prevents rosiglitazone-induced apoptosis of
neointimal SMCs [16]. In addition, many of the target genes,
thought to be involved in the regulation of SMC prolifera-
tion/apoptosis by PPARγ ligands, have been demonstrated
to be either directly regulated by overexpression of PPARγ or
the ligand eﬀect is reversed following pharmacologic inhibi-
tion of PPARγ [16, 19, 48, 50, 53, 54, 61, 78, 79]. These stud-
ies in concert support the concept that the antiproliferative
activity of PPARγ ligands against SMC stems at least in part
fromaligand-dependentactivationofthereceptor.However,
further studies including in particular SMC-speciﬁc PPARγ-
deﬁciency or overexpression are warranted to further sup-
port this notion.
A second important question that arises from this dis-
cussion relates to ligand speciﬁcity and whether the inhibi-
tion of SMC proliferation by agonists for PPARγ is exclu-
sively mediated through this receptor or whether PPARγ lig-
ands may also activate PPARα or δ. Approximately 80% of
the 34 residues deﬁning the ligand binding cavity of PPARγ
are conserved across the three receptor isotypes [11, 20]. In
addition, all three isoforms possess unusually large binding
pockets, compared to other nuclear receptors, which accom-
modate a diverse set of lipophilic acids as ligands [80]. Fur-
thermore, anti-proliferative eﬀects of PPARγ ligands are ob-
served at concentrations considerably higher than their EC50
for transcriptional activation in cell-based transfection as-
saysorininvitrobindingassayswithisolatedligand-binding
domain fragments [15, 81]. Considering this knowledge, at
high concentrations spillover of PPARγ-selective ligands to
PPARα and/or PPARδ is theoretically possible and the an-
tiproliferative activity of TZD observed in PPARγ-deﬁcient
cells could be explained by their binding to and activation
of PPARα or PPARδ. Indeed, activation of PPARα represses
SMC proliferation [82], while PPARδ activation has been re-
ported to stimulate rather than inhibit growth of SMCs [83]
and keratinocytes [84]. Although very few studies have di-
rectly compared the eﬀects of PPARγ,P P A R α,a n dP P A R δ
ligands on SMC function, Lin et al. recently identiﬁed that
the above-described IRF-1-dependent apoptosis induced by
PPARγ ligands is selective and not observed with PPARα or
PPARδ ligands [61]. This study supports ligand selectivity
for PPARγ in SMCs, although detailed studies are required
to further address this question.
4. TZD IN THE TREATMENT OF
CARDIOVASCULAR DISEASE
4.1. Lessonsfromanimalmodels
TZD PPARγ ligands have been demonstrated to prevent the
development of atherosclerosis in several murine atheroscle-
rosis models including the low-density lipoprotein receptor-
deﬁcient (LDLR−/−) and the apolipoprotein E deﬁcient
mouse model (apoE−/−)[ 85–88]. This preventive eﬀect
on hyperlipidemia-induced atherosclerosis occurs indepen-
dently of changes in circulating lipids, blood pressure, glu-
cose, or insulin, implicating direct pleiotropic eﬀects on
the vascular wall. Inhibition of atherosclerosis by TZD lig-
ands in these models appears to be also independent of
their eﬃcacy to improve insulin sensitivity as the prevention
of atherosclerosis is observed in both insulin-sensitive and
insulin-resistant models· [85–88]. The mechanisms respon-
sible for the prevention of atherosclerosis by TZD in these
murine atherosclerosis models likely involve macrophage-
driven processes contributing to atherosclerosis since con-
ditional deletion of PPARγ in macrophages accelerates
atherosclerosis [89]. In addition, speciﬁc deletion of PPARγ
inEChasrecentlybeendemonstratedtoincreasebloodpres-
sure in mice suggesting that PPARγ in EC is an important
regulator of hypertension, which may contribute to the pre-
vention of atherosclerosis in murine models [90].
Consistent with the observations that TZD PPARγ lig-
ands limit SMC proliferation in vitro, Law et al. demon-
strated over a decade ago that the TZD ligand troglitazone
reduces intimal hyperplasia in a ratcarotid arteryballoon in-
jury model [91]. Subsequent studies conﬁrmed these obser-
vations and demonstrated that TZD inhibit intimal hyper-
plasia in models of restenosis in both insulin-resistant and
insulin-sensitive animals [92–95]. Similarly, Joner et al. re-
cently demonstrated the prevention of in-stent restenosis by
TZD ligands using a hypercholesterolemic rabbit atheroscle-
rosis model [96]. Additional beneﬁcial eﬀects of TZD in the
process of neointima formation include accelerated reen-
dothelialization, which is mediated through an enhanced
diﬀerentiation of angiogenic progenitor cells into mature
endothelial cells [97, 98]. As detailed above, the question
as to whether the prevention of neointima formation by
TZD involves a receptor-dependent pathway has been ad-
dressed in a recent study using overexpression of PPARγ.
While in vivo transfer of an adenoviral vector expressing
wild-type PPARγ inhibited SMC proliferation and reduced
neointimaformationafterballooninjury,overexpressionofa
dominant-negative PPARγ mutant increased neointima for-
mation [78]. These studies have provided the ﬁrst in vivo ev-
idence to support a direct role of PPARγ in suppressing the
proliferative response following vascular injury.6 PPAR Research
4.2. ClinicalevidenceforvascularprotectionbyTZD
4.2.1. Carotidarteryintima/mediathickness
Carotid artery intima/media thickness (CIMT) is a well-
described surrogate marker for cardiovascular risk and cor-
relates not only with the presence of cardiovascular risk fac-
tors but also with the risk of future macrovascular events
[99, 100]. The ﬁrst study that used CIMT to assess whether
TZD treatment prevents the progression of atherosclerosis
was performed 10 years ago. In this study 57 patients with
type 2 diabetes were treated with 400mg troglitazone, which
resulted in a signiﬁcant decline in CIMT after 3 months
of treatment [101]. This reduction in CIMT with troglita-
zone has been conﬁrmed in a recent cohort of patients with
insulin-requiring type 2 diabetes [102]. A similar decline
in CIMT was observed a few years later in two indepen-
dent studies performed with pioglitazone [103, 104]. The
recently reported CHICAGO trial (Carotid Intima-Media
Thickness in Atherosclerosis Using Pioglitazone) was a ran-
domized, double-blind, comparator-controlled, multicenter
trial in patients with type 2 diabetes assessing the eﬀect of pi-
oglitazoneversusthesulfonylureaglimepiride onCIMTpro-
gression [105]. In this study of 462 patients the primary end-
point of progression of mean CIMT was less with pioglita-
zone versus glimepiride after 72 weeks. Notably, the beneﬁ-
cial eﬀect of pioglitazone on mean CIMT was similar across
prespeciﬁedsubgroupsbasedonage,sex,systolicbloodpres-
sure, duration of type 2 diabetes, body mass index, HbA(1c)
value,andstatinuse.ThefourthCIMTstudyperformedwith
pioglitazone compared the eﬀects of pioglitazone (45mg/d)
and glimepiride (2.7 +/− 1.6mg/d) in a randomized con-
trolled study of 173 patients with type 2 diabetes [106]. In
this study, CIMT was reduced only in the pioglitazone group
and not in patients treated with glimepiride and this eﬀect
was independent of glycemic control.
Comparable results on CIMT progression have been ob-
tained with rosiglitazone. Sidhu et al. analyzed the eﬀect
of rosiglitazone on CIMT progression in a double-blind,
placebo-controlled randomized study in 92 non-diabetic pa-
tients with documented coronary artery disease [107]. In
this study, rosiglitazone therapy revealed a reduced progres-
sion in CIMT after 48 weeks of treatment. The Rosiglita-
zone Atherosclerosis Study analyzed the eﬀect of TZD treat-
ment on CIMT progression in a mixed patient cohort of 555
subjects with type 2 diabetes or insulin resistance [108]. Al-
thoughinthisstudytherewasnoeﬀectofrosiglitazonetreat-
ment in the mixed population of type 2 diabetes and in-
sulin resistance, in the subanalysis of type 2 diabetic patients
there was a reduced progression of CIMT. A third study re-
ported by Stocker et al. analyzed whether rosiglitazone com-
paredtometformindecreasedCIMTin93subjectswithtype
2 diabetes [109]. In this study, metformin and rosiglitazone
treatment led to similar improvement in glycemic control;
however, CIMT progressed in the metformin group while re-
gression of maximal CIMT was observed in the rosiglitazone
group.
4.2.2. Postangioplastyrestenosis
Takagi et al. [110–112] ﬁrst demonstrated that troglitazone
reduced neointimal tissue proliferation after coronary stent
implantation in patients with type 2 diabetes mellitus. Fol-
lowing the withdrawal of troglitazone from the market, it
was subsequently demonstrated that pioglitazone has similar
eﬀects and signiﬁcantly reduces neointimal tissue prolifera-
tion in patients with type 2 diabetes mellitus [113]. In this
study, 44 patients with type 2 diabetes and 44 stented lesions
were randomized to either pioglitazone therapy or control.
Intravascular ultrasound demonstrated that the neointimal
indexinthepioglitazonegroupwassigniﬁcantlysmallerthan
that in the control group. Similarly, Nishio et al. observed
that the late luminal loss and in-stent restenosis were signiﬁ-
cantlylessinpatientstreatedwithpioglitazone[114].Athird
study performed with pioglitazone demonstrated in a ran-
domized, placebo-controlled, double-blind trial that piogli-
tazone signiﬁcantly reduced neointima volume after coro-
nary stent implantation in patients without diabetes [115].
Comparable results have been obtained with rosiglita-
zone in a prospective, randomized, case-controlled trial in-
volving 95 diabetic patients with coronary artery disease,
which demonstrated that the in-stent restenosis rate was sig-
niﬁcantly reduced in the rosiglitazone group compared with
thecontrolgroup[116].H owever ,asecondstudyofasmaller
cohort of sixteen patients did not observe a signiﬁcant de-
crease in in-stent luminal diameter stenosis measured by
quantitative coronary angiography intravascular ultrasound
[117]. Finally, the third study performed by Wang et al. sug-
gested that the occurrence of coronary events following an-
gioplasty in 71 patients was signiﬁcantly decreased in the
rosiglitazone group at 6-month follow-up [118]. These stud-
ies in concert suggest that TZD therapy in patients under-
going coronary stent implantation may be associated with
less in-stent restenosis and repeated revascularization. This
notion is further supported by two recent meta-analyses
[119, 120]. However, decisions on clinical use of an ad-
junctive TZD therapy following coronary interventions must
await larger double-blind clinical trials.
4.2.3. Cardiovascularoutcomestudies
The beneﬁcial vascular eﬀects observed with TZD pro-
vided the rationale for larger cardiovascular trials and the
ﬁrst results from these studies are beginning to emerge.
The Prospective Pioglitazone Clinical Trial in Macrovascu-
lar Events (PROactive) trail is a prospective, randomized
controlled trial in 5238 patients with type 2 diabetes who
had evidence of macrovascular disease [121]. This study
tested theeﬀects of pioglitazone or placebo in addition to
their glucose-lowering drugs and other medications on a
combined vascular endpoint in patients with known vascu-
lar disease. The broad primary endpoint (the composite of
all-cause mortality, nonfatal myocardial infarction (includ-
ing silent myocardial infarction), stroke, acute coronary syn-
drome,endovascularorsurgicalinterventioninthecoronary
or leg arteries, and amputation above the ankle) was not
statistically diﬀerent between the pioglitazone and placeboF. Gizard and D. Bruemmer 7
arm of the study. However, the study demonstrated a signif-
icant 16% reduction of the main cardiovascular secondary
endpoint of all-cause mortality, myocardial infarction, and
stroke in type 2 diabetic patients treated with pioglitazone.
A recently published subanalysis out of this study further re-
ported the eﬀect of pioglitazone on recurrent myocardial in-
farction in 2,445 patients with type 2 diabetes and previous
myocardial infarction [122]. In this prespeciﬁed endpoint,
pioglitazone had a statistically signiﬁcant beneﬁcial eﬀect on
fatal and nonfatal MI (28% risk reduction) and acute coro-
nary syndrome (37% risk reduction). A second subanalysis
from the PROactive trial in patients with previous stroke
(n = 486 in the pioglitazone group and n = 498 in the
placebo group) further reported that pioglitazone reduced
fatal or nonfatal stroke by 47% [123]. Consistent with the
reported side-eﬀect proﬁle for TZD, the PROactive trial con-
ﬁrmed an increased rate of edema and heart failure in pa-
tients treated with pioglitazone [121]. However, in this con-
text it is important to note that heart failure was a non-
adjudicated event and mortality due to heart failure was not
increased compared to the placebo group.
Currently, trials with rosiglitazone are being performed
to determine whether rosiglitazone aﬀects cardiovascular
outcomes. Three clinical trials are currently testing ap-
proaches that use rosiglitazone to reduce cardiovascular dis-
ease in patients with diabetes: the Action to Control Car-
diovascular Risk in Diabetes (ACCORD) trial [124], the
Bypass Angioplasty Revascularization Investigation 2 Dia-
betes (BARI 2D) trial [125], and The Rosiglitazone Evalu-
ated for Cardiac Outcomes and Regulation of Glycemia in
Diabetes (RECORD) trial [126]. A recent meta-analysis of
trials performed with rosiglitazone reported an association
with a signiﬁcant increase in the risk of myocardial infarc-
tion and with a nonsigniﬁcant increase of the risk of death
from cardiovascular causes [127]. However, the authors of
this meta-analysis acknowledged considerable limitations of
their analysis and the National Institutes of Health (support-
ing the ACCORD and BARI 2D trials) found no evidence
in this analysis to require discontinuing the use of rosigli-
tazone in the trials or to revise the study protocols [128].
Similarly, an interim analysis of the RECORD trial did not
show a statistically signiﬁcant diﬀerence between the rosigli-
tazone group and the control group for the endpoints acute
myocardial infarction and death from cardiovascular causes,
althoughpatientstreatedwithrosiglitazonewereatincreased
risk to develop heart failure [129]. Therefore, completion of
thesestudieswillenablethedeterminationwhetherrosiglita-
zoneprovidesasimilarreductionincardiovascularoutcomes
as seen with pioglitazone and will aid to determine the most
appropriate combination therapies for patients with type 2
diabetes.
5. SUMMARY AND CONCLUSIONS
Research performed over the last decade has highlighted an
important role for TZD-induced PPARγ activation in vascu-
lar cells. TZD exert a broad spectrum of anti-inﬂammatory
and anti-proliferative on all cell types participating in the de-
velopment of cardiovascular diseases. A wealth of evidence
from preclinical and clinical studies supports that these
pleiotropic eﬀects of TZD translate into reduced atheroscle-
rosis and failure of coronary angioplasty as the primary ap-
proach to treat luminal obstruction. The PROactive trial was
the ﬁrst cardiovascular outcome trial to demonstrate that pi-
oglitazone decreases all-cause mortality, myocardial infarc-
tion, and stroke in patients with type 2 diabetes. Further
studies including the ACCORD, RECORD, and BARI 2D
trials will determine whether similar eﬀects are seen with
rosiglitazone and outline ideal treatment strategies to reduce
cardiovascular disease in patients with type 2 diabetes.
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